These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19769084)

  • 1. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].
    Walter M
    MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of gender and anchor drugs on TDF renal toxicity.
    Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HIV agents. Trying times for tenofovir and abacavir.
    TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment options for lipodystrophy in HIV-positive patients.
    Behrens GM
    Expert Opin Pharmacother; 2008 Jan; 9(1):39-52. PubMed ID: 18076337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
    Stephan C
    Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 10. Fatal lactic acidosis associated with tenofovir and abacavir.
    Giola M; Basilico C; Grossi P
    Int J Infect Dis; 2005 Jul; 9(4):228-9. PubMed ID: 15916912
    [No Abstract]   [Full Text] [Related]  

  • 11. EU issues warning about HAART regimen.
    AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094
    [No Abstract]   [Full Text] [Related]  

  • 12. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
    Negredo E; Domingo P; Pérez-Álvarez N; Gutiérrez M; Mateo G; Puig J; Escrig R; Echeverría P; Bonjoch A; Clotet B
    J Antimicrob Chemother; 2014 Dec; 69(12):3368-71. PubMed ID: 25125679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.
    Spiegel LR; Schrier PB; Shah HH
    Ren Fail; 2013 Sep; 35(8):1186-90. PubMed ID: 23883141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
    Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
    Nolan D; Mallal S
    J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
    Prescrire Int; 2014 May; 23(149):124-5. PubMed ID: 24926511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
    Silkiss RZ; Lee H; Gills Ray VL
    Arch Ophthalmol; 2009 Mar; 127(3):345-6. PubMed ID: 19273808
    [No Abstract]   [Full Text] [Related]  

  • 20. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.